Table 1. Characteristics of case-control studies included in the meta-analysis.
First author | Year | Country | Ethnicity | Type | Sample size | Genotyping method | HWE | Score |
---|---|---|---|---|---|---|---|---|
Case/Control | ||||||||
Bodelon C | 2013 | USA | Caucasian | BC | 840/801 | IGGMP | Yes | 6 |
Bracci PM | 2010 | USA + UK | Caucasian | NHL | 255/511 | IGGMP | Yes | 8 |
Cacina C | 2012 | Turkey | Asian | EC | 113/139 | PCR-RFLP | Yes | 6 |
Cai C | 2013 | China | Asian | RC | 322/402 | PCR-RFLP | Yes | 7 |
de Lourdes Perim A | 2013 | Brazil | Caucasian | ALL | 54/58 | PCR-RFLP | Yes | 6 |
de Oliveira CE | 2007 | Brazil | Caucasian | CML | 25/60 | PCR-RFLP | Yes | 5 |
de Oliveira KB | 2009 | Brazil | Caucasian | BC | 103/97 | PCR-RFLP | Yes | 5 |
de Oliveira KB | 2010 | Brazil | Caucasian | NHL + HL | 106/90 | PCR-RFLP | Yes | 5 |
Dimberg J | 2007 | Sweden | Caucasian | CRC | 151/141 | PCR-RFLP | Yes | 5 |
Gawron AJ | 2011 | Poland | Caucasian | GC | 292/414 | TaqMan | Yes | 7 |
Hidalgo-Pascual M | 2007 | Spain | Caucasian | CRC | 349/516 | Real-time PCR | Yes | 6 |
Hirata H | 2007 | Japan | Asian | PC | 167/167 | PCR-RFLP | Yes | 5 |
Isman FK | 2012 | Turkey | Asian | PC | 152/149 | PCR-RFLP | Yes | 7 |
Khademi B | 2008 | Iran | Asian | HC + NC | 156/262 | PCR-RFLP | Yes | 6 |
Kontogianni P | 2013 | Greece | Caucasian | BC | 261/480 | PCR-RFLP | Yes | 6 |
Kruszyna L | 2010 | Poland | Caucasian | BC | 193/199 | PCR-RFLP | Yes | 6 |
Kruszyna L | 2010 | Poland | Caucasian | LAC | 118/250 | PCR-RFLP | Yes | 6 |
Kucukgergin C | 2012 | Turkey | Asian | BLC | 142/197 | PCR-RFLP | Yes | 7 |
Lee YL | 2011 | China | Asian | LC | 247/328 | PCR-RFLP | Yes | 7 |
Liarmakopoulos E | 2013 | Greece | Caucasian | GC | 88/480 | PCR-RFLP | Yes | 6 |
Lin GT | 2009 | China | Asian | BC | 220/334 | PCR-RFLP | Yes | 4 |
Maley SN | 2009 | USA | Caucasian | CC | 899/820 | TaqMan | Yes | 7 |
Mazur G | 2013 | Poland | Caucasian | MM | 54/75 | PCR-RFLP | Yes | 4 |
Pemberton NC | 2006 | UK | Caucasian | CLL | 323/108 | PCR-RFLP | Yes | 5 |
Petersen DC | 2008 | Australia | Caucasian | PC | 815/727 | TaqMan | Yes | 6 |
Razmkhah M | 2013 | Iran | Asian | GC + CC | 233/262 | PCR-RFLP | Yes | 4 |
Razmkhah M | 2005 | Iran | Asian | BC | 278/181 | PCR-RFLP | Yes | 6 |
Razmkhah M | 2005 | Iran | Asian | LC | 72/262 | PCR-RFLP | Yes | 4 |
Shi MD | 2013 | China | Asian | CRC | 258/300 | DHPLC | Yes | 5 |
Singh V | 2014 | India | Asian | BLC | 200/200 | PCR-RFLP | Yes | 7 |
Tee YT | 2012 | China | Asian | CC | 137/337 | PCR-RFLP | Yes | 7 |
Vairaktaris E | 2008 | Europe | Caucasian | OC | 159/101 | PCR-RFLP | Yes | 6 |
Vázquez-Lavista LG | 2009 | Mexico | Mixed | BLC | 47/126 | PCR-RFLP | Yes | 7 |
Wong HL | 2010 | USA | Mixed | NHL | 233/240 | TaqMan | Yes | 7 |
BC = breast cancer; EC = endometrial cancer; RC = renal cancer; ALL = acute lymphatic leukaemia; CML = chronic myeloid leukaemia; NHL non-Hodgkin’s lymphoma; HL = Hodgkin’s lymphoma; CRC = colorectal cancer; GC = gastric cancer; PC = prostate cancer; HC = head cancer; NC = neck cancer; LAC = laryngeal cancer; BLC = bladder cancer; LC = lung cancer; CC = cervical cancer; MM = multiple myeloma; CLL = chronic lymphocytic leukaemia; OC = ovarian cancer; IGGMP = Illumina Golden Gate multiplex platform; PCR-RFLP = polymerase chain reaction-restricted fragment length polymorphism; DHPLC = denaturing high performance liquid chromatography.